Ingredient profile
titanium dioxide 6.15
Raters disagreeCAS 13463-67-7
At least one of our safety lists speaks to this ingredient.
Raters don't agree. Here's where each one stands
Safe
Greenlens Ingredient Scan
Independent
Greenlens Precautionary Screen
Independent
Greenlens Tolerance Screen
Independent
Caution
IARC Monographs
Government
Concern
ANSES Endocrine Disruptors
Government
Where each list lands
Funding shown- Caution
IARC Monographs
Government
Titanium dioxide is classified possibly carcinogenic to humans — the evidence is for INHALED respirable powder (loose powders/sprays), not the bound pigment in a cream or lotion. (IARC Monographs, Vol. 93)
- Concern
ANSES Endocrine Disruptors
Government
An ANSES endocrine-disruptor candidate (SNPE2); classified Carc. 2 for the inhalable powder form (a concern for loose powders/aerosols). (ANSES — French national strategy on endocrine disruptors (SNPE2))
- Safe
Also screened — not on these lists
- Health Canada Ingredient Hotlist
- California Proposition 65
- US NTP Report on Carcinogens
- EU Microplastics Restriction
- EU Harmonised Classification (CLP Annex VI)
Where regulators stand
Shown side by side, never combinedEach jurisdiction is reported on its own terms, from its own official lists. Where they disagree, that disagreement is the finding. Absence from a list is never a safety claim.
European Union
RestrictedAllowed only under stated conditions or limits.
- European Commission · EU Cosmetics Regulation Annex III (restricted)Listed in Annex III of the EU Cosmetics Regulation (ref 321) — allowed only under restrictions (max (a) 25 %; (b) 1,4 % for general consumers, and 1.1 % for professional use.).
Canada
No listing foundNot on the lists we hold for this jurisdiction. That is an absence of a listing, not a safety finding.
Checked: Health Canada Cosmetic Ingredient Hotlist.
California
No listing foundNot on the lists we hold for this jurisdiction. That is an absence of a listing, not a safety finding.
Notes
- ANSES CMR-listed
- IARC possible carcinogen (Group 2B)
